by Portfolio Grader | July 19, 2013 3:00 pm
This week, the overall grades of three Pharmaceutical stocks are lower, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
VIVUS Inc.’s (NASDAQ:VVUS) rating falls to a D (“sell”) this week, down from C (“hold”) the week prior. VIVUS is a biopharmaceutical company engaged in the development and commercialization of therapeutic products for large underserved markets. For Portfolio Grader’s specific subcategory of Equity, VVUS also gets an F. As of July 19, 2013, 29.3% of outstanding VIVUS Inc. shares were held short. For a full analysis of VVUS stock, visit Portfolio Grader.
The rating of Cempra Inc. (NASDAQ:CEMP) slips from a C to a D. Cempra manufactures and markets pharmaceutical products. The stock gets F’s in Equity and Cash Flow. To get an in-depth look at CEMP, get Portfolio Grader’s complete analysis of CEMP stock.
Corcept Therapeutics (NASDAQ:CORT) earns an F (“strong sell”) this week, moving down from last week’s grade of D (“sell”). Corcept Therapeutics engages in the discovery, development, and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders. The stock gets F’s in Equity and Cash Flow. For more information, get Portfolio Grader’s complete analysis of CORT stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
Source URL: http://investorplace.com/2013/07/3-pharmaceutical-stocks-to-sell-now-vvus-cemp-cort-15/
Short URL: http://invstplc.com/1fuaEX6